Why the did Dr Donut commit to an unrealistic timeline?
Water under the bridge at this point I would say.
Here is the new timeline.
“The answer to both questions is that the data will be - the trial will be finished in end of 2018. It will be a full 104 weeks, plus a 57 week from the previous 002 study. So, total of three-year cumulated daily dosing of ANAVEX 2-73. The answer to the second question is, we do not need that data or we do not have to wait for the end of that extension study to initiate a larger Alzheimer’s study. As a matter of fact, it will start before that trial will be finishing.”
Sounds like a firm commitment to me.
The Sullivan article left me with the impression that Anavex was struggling to get patients to tolerate the higher doses. Much of the safety data appears to represent patients who were taking doses that did not show hints of efficacy. Seems logical that they went from the original 26 week trial to a 52 week trial and then ran a two year trial with the same parameters instead of moving to the next phase trial.
How could they move forward if toxicity prevented admission of higher doses and the lower doses showed no hints of efficacy?
News 
Market Data 
Discover 
